OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced …
OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced …
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a randomized, controlled, investigator-sponsored Phase 2 trial of OGX-427 in men with metastatic prostate cancer.
Read more on CNW Group via Yahoo! Finance
Categories: Breast Cancer Tumor Tags: advanced, Announces, evaluating, initiation, OGX427, OncoGenex, Pharmaceuticals, Phase, Treatment, Trial
Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate that is being developed for the treatment of metastatic renal cancer.
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Treatment Tags: affiliate, Agensys, AGS16M8F, Announces, Astellas, cancer, Clinical, initiation, Phase, Renal, Trial
Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI …
Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI …
MISSION VIEJO, Calif.—-Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health’s , National Institute of Allergy and Infectious Diseases Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal tract.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Research Tags: 10150, AEOL, Aeolus, Announces, Countermeasure, initiation, Medical, Pharmaceuticals, second, Study
Supplement blocks the initiation of breast cell mutations by estrogens
Supplement blocks the initiation of breast cell mutations by estrogens
( EQ Biosciences, Inc. ) EQ Biosciences Inc. launches Prevennia, a dietary supplement that blocks the initiation of breast cell mutation.
Read more on EurekAlert!
Categories: Genetic Testing For Breast Cancer Tags: blocks, breast, Cell, estrogens, initiation, mutations, Supplement